|Bid||9.95 x 4000|
|Ask||9.96 x 3200|
|Day's Range||9.94 - 9.95|
|52 Week Range||9.70 - 10.50|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
, a biotechnology company focused on hematopoietic cell transplant therapies, and result in Jasper Therapeutics becoming a publicly-listed company. Under the terms of the agreement, Amplitude Healthcare shareholders will retain ownership of only 20.
Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, anticipated to occur in the third quarter 2021, the combined company will be renamed Jasper Therapeutics, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol "JSPR."
The big shareholder groups in Amplitude Healthcare Acquisition Corporation ( NASDAQ:AMHC ) have power over the company...